NEXENTIS TECHNOLOGIES INC. Proceeds from Lines of Credit
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Proceeds from Lines of Credit of $1.34 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-08-13
- NEXENTIS TECHNOLOGIES INC. proceeds from lines of credit for the quarter ending 2025-12-31 was $235.00K.
- NEXENTIS TECHNOLOGIES INC. proceeds from lines of credit for the quarter ending 2025-09-30 was $0.00.
- NEXENTIS TECHNOLOGIES INC. proceeds from lines of credit for the quarter ending 2025-06-30 was $0.00.
- NEXENTIS TECHNOLOGIES INC. proceeds from lines of credit for the quarter ending 2025-03-31 was $1.10M.
- NEXENTIS TECHNOLOGIES INC. proceeds from lines of credit for fiscal 2025 was $1.34M.
USD
| Period end | Proceeds from Lines of Credit 3 month | Proceeds from Lines of Credit 6 month | Proceeds from Lines of Credit 9 month | Proceeds from Lines of Credit 12 month |
|---|---|---|---|---|
| 2025-12-31 | $235.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $235.00K derived: sum of 2 quarters · filed 2026-03-31 | $235.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.34M 10-K · filed 2026-03-31 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $1.10M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.10M 10-Q · filed 2026-08-13 | ||
| 2025-03-31 | $1.10M 10-Q · filed 2026-05-14 |
EUR
| Period end | Proceeds from Lines of Credit 12 month |
|---|---|
| 2025-12-31 | 1.25M EUR 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |